Follow-up of low-risk patients with differentiated thyroid carcinoma: A European perspective

European Journal of Endocrinology

Volumn 150, Issue 2, 2004, Pages 105-112

  Schlumberger, Martin ^a   Berg, Gertrud ^b   Cohen, Ohand ^c   Duntas, Leonidas ^d   Jamar, François ^e   Jarzab, Barbara ^f   Limbert, Eduard ^g   Lind, Peter ^h   Pacini, Furio ⁱ   Reiners, Christoph ^j   Sánchez Franco, Franco ^k   Toft, Anthony ^l   Wiersinga, Wilmar M ^m  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c SHEBA MEDICAL CENTER   (Israel)

^d Evgenidion Hospital   (Greece)

^e UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g Portuguese Cancer Institute   (Portugal)

^h Positron Emission Tomography Center   (Austria)

ⁱ UNIVERSITY OF SIENA   (Italy)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 125; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIAGNOSTIC VALUE; DRUG SAFETY; EARLY DIAGNOSIS; ECHOGRAPHY; EUROPE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; LONG TERM CARE; MEDICAL LITERATURE; NECK CANCER; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; CLINICAL PROTOCOLS; DECISION TREES; EUROPE; FOLLOW-UP STUDIES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES; RECOMBINANT PROTEINS; RISK; THYROGLOBULIN; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 12144290968     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500105     Document Type: Review

References (44)

1. Schlumberger MJ. Medical progress: papillary and follicular thyroid carcinoma. New England Journal of Medicine 1998 338 297-306.
2. Lind P, Kumnig G, Heinisch M, Igerc I, Mikosch P, Gallowitsch HJ et al. Iodine supplementation in Austria: methods and results. Thyroid 2002 12 903-907.
3. Parkin DM, Whelan SL, Ferlay J, Raymond L & Young J. Cancer incidence in five continents. In IARC Scientific Publications No. 143. Lyon: IARC vol VII, 1997.
4. Colonna M, Grosclaude P, Remontet L, Schvartz C, Mace-Lesech J, Velten M et al. Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997). European Journal of Cancer 2002 38 1762-1768.
5. Gomez Segovia I, Gallowitsch HJ, Kresnik E, Kumnig G, Igerc I, Matschnig S et al. Descriptive epidemiology of thyroid carcinoma in Carinthia/Austria 1984-2001: histopathological features and tumor classification of 734 cases under elevated iodination of table salt since 1990. Population-based age-stratified analysis on thyroid carcinoma incidence. Thyroid 2004 (In Press).
6. Schlumberger MJ, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. Journal of Nuclear Medicine 1996 37 598-605.
7. Biondi B, Palmieri EA, Lombardi G & Fazio S. Effects of subclinical thyroid dysfunction on the heart. Annals of Internal Medicine 2002 137 909-914.
8. Reiners C, Luster M & Lassmann M. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine- 131. Journal of Endocrinological Investigation 1999 22 (Suppl) 17-24.
9. Schlumberger MJ & Pacini F. Papilliary and follicular thyroid carcinoma. pp 108-240. Thyroid Tumors, edn 2. Paris: Editions Nucleon, 2003.
10. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA et al. Serum thyroglobudin antibodies: prevalence, influence on serum thyroglobulin measurements, and prognostic significance in patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1998 83 1121-1127.
11. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Annals of Internal Medicine 2003 139 346-351.
12. Bartalena L, Martino E, Pacchiarotti A, Grasso L, Aghini-Lombardi F, Buratti L et al. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. Journal of Clinical Endocrinology and Metabolism 1987 64 849-855.
13. Cailleux AF, Baudin E, Travagli JP, Ricard M & Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? Journal of Clinical Endocrinology and Metabolism 2000 85 175-178.
14. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D & Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. Journal of Clinical Endocrinology and Metabolism 2002 87 1499-1501.
15. 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. The role for neck ultrasonography. European Journal of Endocrinology 2003 148 18-24.
16. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM & Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. European Journal of Nuclear Medicine and Imaging 2002 29 783-788.
17. 131I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. Journal of Nuclear Medicine 2001 42 1470-1475.
18. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism 1999 84 3877-3885.
19. Haugen BR, Ridgway EC, McLaughlin B & McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human TSH. Thyroid 2002 12 37-43.
20. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine 1997 337 888-896.
21. Mazzaferri EL & Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? Journal of Clinical Endocrinology and Metabolism 2002 87 1490-1498.
22. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II Study). Journal of Clinical Endocrinology and Metabolism 1994 78 188-196.
23. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C et al. rhTSH-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 3668-3673.
24. Robbins RJ, Chou JT, Fleisher M, Larson SM & Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? Journal of Clinical Endocrinology and Metabolism 2002 87 3242-3247.
25. Wartofsky L. Management of low risk well-differentiated thyroid cancer based only upon thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002 12 583-590.
26. Berg G, Lindstedt G, Suurküla M & Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone (rhTSH). Journal of Endocrinological Investigation 2002 25 44-52.
27. Dow KH, Ferrell BR & Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 613-619.
28. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid cancer: single-center study of 54 patients. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 1077-1086.
29. Lippi F, Capezzone M, Angelini F, Taddei D. Molinaro E, Pinchera A et al. Radioiodine treatment of differentiated thyroid cancer on L-thyroxine plus recombinant human TSH (rhTSH): initial single-center experience. European Journal of Endocrinology 2000 144 5-11.
30. Luster M, Lassmann M, Haenscheid M, Michalowski U, Incerti C & Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2000 85 3640-3645.
31. Pacini E, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C et al. Prediction of disease status by recombinant human TSH stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2001 86 5686-5690.
32. Lees W, Mansberg R, Roberts J, Towson J, Chua E & Turtle J. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. European Journal of Nuclear Medicine and Molecular Imaging 2002 29 1421-1427.
33. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Gomez MJ, Rodriguez-Fernandez A, Muros T et al. Utility of fluorine-18-fluorurodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. American Journal of Surgery 2000 179 457-461.
34. Park HM, Perkins OW, Edmondson JW, Schnute RB & Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994 4 49-54.
35. Postgard P, Jimmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G et al. Stunning of iodine transport by (131)I irradiation in cultured thyroid epithelial cells. Journal of Nuclear Medicine 2002 43 828-834.
36. Frasoldati A, Presenti M, Gallo M, Caroggio A, Salvo D & Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003 97 90-96.
37. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002 12 707-711.
38. Demers LM & Spencer CA. 7-13-2002 Laboratory support for the diagnosis and monitoring of thyroid disease http://www.nacb.org/lmpg/thyroid/LMPH.stm
39. Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 1992 74 1401-1404.
40. Arturi F, Russo D, Giuffrida D, Ippolito A, Perroti N, Vigneri R et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. Journal of Clinical Endocrinology and Metabolism 1997 82 1638-1641.
41. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP & Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal in thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 2003 88 1107-1111.
42. 131I activities versus untreated patients. Journal of Clinical Endocrinology and Metabolism 2001 86 4092-4097.
43. 18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2002 29 641-647.
44. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 1433-1441.